The FDA has updated its guidance clearly allowing reimbursements to patients in clinical trials for lodging and travel to and from trial sites, and these payments are not considered to raise issues regarding undue influence. However, other aspects of proposed payment for participation could present an undue influence, and ethics reviews should continue to examine how much compensation participants receive. (CenterWatch)